NCT07010159Phase 2, phase 3Recruiting

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

Study sponsor: Kiniksa Pharmaceuticals International, plc · KNSA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-31Estimated
Enrollment · participants325Estimated
Source updated2026-10-28Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 160 participants

Before: 165 participants (planned). After: 325 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview